The legacy status of Viagra, and its parent firm copyright, presents a challenging question for shareholders . While revenues initially surged, the approaching patent expiration and growing generic presence https://minarhsa957863.blogofoto.com/72979564/the-blue-pill-and-the-pharmaceutical-industry-a-speculative-investment